Lisa Butterfield PhD, speaking during a Congressional briefing on Capitol Hill, discussed advances in cancer immunotherapy research as well as the need for continued federal funding.
Dr. Butterfield is a Professor of Medicine, Surgery, Immunology and Clinical and Translational Science—and Director of the UPMC Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory—at the University of Pittsburgh School of Medicine. She is also President of the Society for Immunotherapy of Cancer, which co-hosted the briefing in partnership with the American Association for Cancer Research. The event was titled, “Progress in Immunotherapy: Delivering Hope and Clinical Benefit to Cancer Patients.”
A leader in cancer immunology research, Dr. Butterfield told the July 19, 2017, briefing audience that stable and increased federal research funding will enable continued advances in the field, as well as support young career scientists in labs performing immunotherapy research.